| Dr Charles David Fritch, MD | |
|
8501 Brimhall Rd, 402, Bakersfield, CA 93312-2257 | |
| (661) 665-2020 | |
| (661) 829-6990 |
| Full Name | Dr Charles David Fritch |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 8501 Brimhall Rd, Bakersfield, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982639159 | NPI | - | NPPES |
| 770338461 | Other | CA | TAX ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | C33729 (California) | Primary |
| Entity Name | Charles D. Fritch, M.d., Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124200316 PECOS PAC ID: 6800871757 Enrollment ID: O20040623001029 |
News Archive
Some of the federal healthcare law's requirements related to insurance exchanges threaten the autonomy of U.S. states, which need more support in establishing the marketplaces, state governors said in a letter released on Thursday. "The decision to implement health insurance exchanges requires a number of complex policy decisions amid aggressive timelines," wrote the National Governors Association in a letter to U.S. Health Secretary Kathleen Sebelius dated Nov. 2.
A study from EPFL's (Ecole Polytechnique F-d-rale de Lausanne) Laboratory of Neuroenergetics and Cellular Dynamics in Lausanne Switzerland, published today in the Journal of Neuroscience, may lead to new forms of treatment following a better understanding of how Amyloid-Beta found in cerebral plaques, typically present in the brain of Alzheimer's patients, may lead to neurodegeneration.
Obese patients with obstructive sleep apnea who lose significant weight through surgery may still not be cured of their sleep disorder, study findings indicate.
Xcelience, a leader in early development services, recognizes that providing access to a third, dedicated Xcelodose® 120S precision powder micro-dosing system in the experimental area enables clients to accelerate drug development with preliminary compound evaluation, earlier go/ no-go decisions and flexible options for experimental studies.
An established class of drugs, traditionally used to control HIV/AIDS infections, could soon be harnessed to treat the leading cause of blindness and visual impairment in the UK, for which currently there exists no cure.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles David Fritch, MD 8501 Brimhall Rd, 402, Bakersfield, CA 93312-2257 Ph: (661) 665-2020 | Dr Charles David Fritch, MD 8501 Brimhall Rd, 402, Bakersfield, CA 93312-2257 Ph: (661) 665-2020 |
News Archive
Some of the federal healthcare law's requirements related to insurance exchanges threaten the autonomy of U.S. states, which need more support in establishing the marketplaces, state governors said in a letter released on Thursday. "The decision to implement health insurance exchanges requires a number of complex policy decisions amid aggressive timelines," wrote the National Governors Association in a letter to U.S. Health Secretary Kathleen Sebelius dated Nov. 2.
A study from EPFL's (Ecole Polytechnique F-d-rale de Lausanne) Laboratory of Neuroenergetics and Cellular Dynamics in Lausanne Switzerland, published today in the Journal of Neuroscience, may lead to new forms of treatment following a better understanding of how Amyloid-Beta found in cerebral plaques, typically present in the brain of Alzheimer's patients, may lead to neurodegeneration.
Obese patients with obstructive sleep apnea who lose significant weight through surgery may still not be cured of their sleep disorder, study findings indicate.
Xcelience, a leader in early development services, recognizes that providing access to a third, dedicated Xcelodose® 120S precision powder micro-dosing system in the experimental area enables clients to accelerate drug development with preliminary compound evaluation, earlier go/ no-go decisions and flexible options for experimental studies.
An established class of drugs, traditionally used to control HIV/AIDS infections, could soon be harnessed to treat the leading cause of blindness and visual impairment in the UK, for which currently there exists no cure.
› Verified 3 days ago
Dr. Richard Tak-kam Ling, M.D., PH.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2325 17th St, Bakersfield, CA 93301 Phone: 661-321-9633 Fax: 661-631-8888 | |
Helen Yiyun Jiang, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1721 Westwind Dr Ste B, Bakersfield, CA 93301 Phone: 248-635-7173 | |
Anuj Chawla, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9500 Stockdale Hwy Ste 108, Bakersfield, CA 93311 Phone: 661-663-8500 Fax: 661-663-8688 | |
Dr. Ronald Lee Morton, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1001 Tower Way, Suite 150, Bakersfield, CA 93309 Phone: 661-327-4499 Fax: 661-327-4381 | |
Dr. Andrew Allen Kao, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4105 Empire Dr, Bakersfield, CA 93309 Phone: 661-325-3937 | |
Daniel H Chang, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4101 Empire Dr, Suite 120, Bakersfield, CA 93309 Phone: 661-325-3937 Fax: 661-283-3937 | |
Dr. Cary Hatton Freeman, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2201 Mt Vernon Ave, Ste 211, Bakersfield, CA 93306 Phone: 661-872-7000 Fax: 661-872-0499 |